While the inhibitory receptor TIGIT, which is expressed on T and NK cells and also binds to CD155, is already investigated as a target in anti-tumor [54] and anti-HIV-1 [55] therapies, the inhibitory interactions between CD155 and KIR2DL5 might represent a second axis that can be targeted by future therapeutic approaches. Here, TIGIT is linked to neoplasm.